Altamira expects total cash needs in 2024 to be in the range of $5.8 million to $7.0 million. During the third quarter of 2024, the Company raised $0.7 million from share issuances under the 2022 Commitment Purchase Agreement with Lincoln Park Capital Fund and gross proceeds of $4.0 million upfront from a public offering of common shares with milestone-linked warrants.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTO:
- Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
- Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
- Altamira Issues Pre-Funded Share Purchase Warrant
- Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering
- Altamira Therapeutics announces pricing of $12M offering